Drugs / Ataciguat
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02481258 | Jun 2015 → Jul 2018 | aortic valve stenosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00799656 | Nov 2008 → Jun 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00443287 | Feb 2007 → Oct 2008 | intermittent vascular claudication | Sanofi | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07001800 | Jun 2025 → Aug 2028 expected | aortic valve stenosis | Kardigan, Inc. | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02049203 Comparator | Jan 2014 → Mar 2015 | aortic valve stenosis | Jordan D. Miller, Ph.D. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ataciguat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02049203 ↗ |
| Known as | HMR1766 | “Drug: ataciguat (HMR1766)” NCT00799656 ↗ |
| Action | Restore | “reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat” PMID 39989354 ↗ Feb 2025 |
| Modality | Small molecule | — CHEMBL2107729 ↗ |
| Route | Oral | “oral administration” NCT00443287 ↗ |